Study of Ataluren (PTC124) in Hemophilia A and B

Stopped early · Phase 2

Conditions studied: Hemophilia A, Hemophilia B

In brief

Hemophilia A (HA) and hemophilia B (HB) are inherited bleeding disorders caused by mutations in the gene for factor VIII (FVIII) and factor IX (FIX), respectively. These proteins are essential for blood clotting. The lack of FVIII/FIX can produce bleeding episodes that cause damage of the bone, muscles, joints, and tissues. A specific type of mutation, called a nonsense (premature stop codon) mutation, is the cause of the disease in approximately 10-30% of participants with hemophilia and results in severe manifestations. Ataluren (PTC124) is an orally delivered, investigational drug that acts to overcome the effects of the premature stop codon, potentially enabling the production of functional FVIII/FIX. This study is a Phase 2a trial evaluating the safety and efficacy of ataluren in participants with HA or HB due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase FVIII/FIX activity levels.

Key facts

Study ID

NCT00947193

Run by

PTC Therapeutics

People needed

13

Starts

2009-10-14

Expected to finish

2011-08-30

Last updated by the study team

2020-06-16

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent
• Age ≥18 years
• Presence of a nonsense mutation as the sole disease-causing mutation in the FVIII or FIX gene
• At least 20 prior treatments with FVIII or FIX concentrates
• Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures

You may not qualify if…

• Known hypersensitivity to any of the ingredients or excipients of the study drug
• Any history of prior anti-FVIII/FIX inhibitors
• Unable or unwilling to forego prophylactic FVIII/FIX concentrate use during the screening and on-study periods (Note: Participants were allowed use of FVIII/FIX concentrates for treatment of bleeding episodes while on study)

Where it is running

• The Bleeding and Clotting Disorders Institute — Peoria, Illinois, United States
• St. Vincent Indianapolis Hospital — Indianapolis, Indiana, United States
• New England Hemophilia Center — Worcester, Massachusetts, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Vanderbilt Hemostatis and Thrombosis Clinic — Nashville, Tennessee, United States
• Puget Sound Blood Center — Seattle, Washington, United States
• St. Paul's Hospital — Vancouver, British Columbia, Canada
• Hôpital Cardiologique — Lille, France
• Hôpital Edouard Herriot — Lyon, France
• Hôpital Necker Enfants Malades — Paris, France
• Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni — Florence, Italy
• A.Bianchi Bonomi Hemophilia and Thrombosis Center — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.